ABY-029

N/A

Report date: 2026/05/08 20:02:52
NME

Base Information

Drug NameABY-029
Drug Alias NameABY-029 trifluoroacetate saltIRDye 800CW maleimide-labeled affibody peptidefluorescently-labeled Anti-EGFR affibody moleculeABY-029
ClassificationDiagnostic agent (In vivo)Small molecules
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsBrain NeoplasmsHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and Neck +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesDartmouth CollegeAffibody AbLi-Cor Bioscience
China Registration ClassN/A

Develop Information

Active CompaniesDartmouth CollegeAffibody AbLi-Cor Bioscience
Inactive CompaniesN/A
Active IndicationsBrain NeoplasmsSquamous Cell Carcinoma of Head and NeckGlioma
Inactive IndicationsHead and Neck NeoplasmsSarcoma

Other Information

ATC CodeN/A
Related LinksN/A